Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients
International Journal of Clinical Oncology, 11/02/09
Meguro M et al. – The regimen of oral UFT plus LV produced only low–grade toxicity and was convenient for outpatients. It appears that the initial UFT dose might be associated with the development of toxicity in the oral UFT plus LV regimen.
Related Articles
Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II
Cancer Epidemiology, Biomarkers & Prevention, 10/28/09
Relevance Score: 72%
Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
Cancer Causes and Control, 10/02/09
Relevance Score: 72%
P73 expression and its clinical significance in colorectal cancer
Colorectal Disease, 10/19/09
Relevance Score: 71%
trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II
Cancer Causes and Control, 10/28/09
Relevance Score: 70%
Association of clinicopathological features with UbcH10 expression in colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09
Relevance Score: 70%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


